AAKP's role in Clinical Trials and Market Research
AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice and experience with renal companies and clinical trials - to create more and better treatment options for kidney patients, so they can achieve their aspirations.
You may have heard the term “clinical trials” but wonder what that means. Is a clinical trial something you can participate in? What do you need to do to get started? We have pulled together some information that you might find helpful as you decide whether you would like to participate in a clinical trial.
View our Clinical Trial Brochure
Learn More About AAKP Awareness Campaigns
Clinical Trials and Market Research Opportunities
Below is a list of the Clinical Trials and Market Research opportunities that AAKP is partnering to raise awareness of. You can also use the search tool below to be matched to even more opportunities.
| Name | Description | Learn More |
|---|---|---|
| PREVAIL (IgAN) | PREVAIL is a clinical study to learn more about the effect of felzartamab on proteinuria (too much protein in the urine) and the kidneys’ ability to filter blood in adults with IgAN. | Click here to read more about this opportunity. |
| PROMINENT (PMN) | PROMINENT is a clinical study to learn more about the effect of felzartamab on the buildup of antibodies in the filters (glomeruli) of the kidneys in adults diagnosed with primary membranous nephropathy, known as PMN. | Click here to read more about this opportunity. |
| DYADS sample collection study | Join the DYADS sample collection study to help develop and validate an investigational non-invasive test that assesses whether an unborn baby may be affected by ARPKD. Participation involves collecting blood and/or cheek swab samples and health information from both the biological female parent who is a carrier and their biological children. The investigational test is being developed to be used during pregnancy for people who are carriers of certain genetic conditions who want to help determine whether their unborn baby may have inherited a genetic condition. Your participation in this study is critical to expanding the future of prenatal genetic screening and helping more families plan for their children’s future. | Click here to read more about this opportunity. |
| HIB-202-101 Lupus Nephritis Study | This clinical research study is testing an investigational medication for adults with lupus nephritis. The goal of the study is to see if the study medication can help with symptoms of lupus nephritis and stop the condition from getting worse. | Click here to read more about this opportunity. |
| TwoPlus Study | The TwoPlus Clinical Trial is funded by Patient-Centered Outcomes Research Institute (PCORI). The study takes place at ten healthcare systems and more than fifty outpatient dialysis units in the United States. This study takes an unbiased approach to rigorously compare the effectiveness of personalized, incremental hemodialysis and traditional hemodialysis. This study will help patients, care partners, and providers make better decisions about what treatment plan is best for each individual. Studies have found that an incremental treatment plan for hemodialysis (two hemodialysis sessions per week and then three hemodialysis sessions per week) is both safe and effective for patients who have residual kidney function—but not for those who do not have appreciable residual kidney function. | Click here to read more about this opportunity. |
| KYSA-1 | The KYSA-1 trial is designed to evaluate if Chimeric Antigen Receptor (CAR) T-cell therapy is safe in people who have active lupus nephritis (LN) and do not get better with standard therapies. CAR T-cell therapy is a type of treatment called immunotherapy. This means it works with your immune system to target B cells in your body. Unhealthy B cells drive inflammation and disease activity in LN. | Click here to read more about this opportunity. |
| SAFE Kidney II | The purpose of this study is to evaluate the safety, tolerability, and efficacy of AntiBKV in reducing BK viremia and progression to biopsy-confirmed BKVAN in Kidney Transplant Recipients (KTRs). The study includes two parts. The phase II part will evaluate the safety of AntiBKV in KTRs and establish proof of concept. The phase III part will assess the efficacy of AntiBKV in KTRs. | Click here to read more about this opportunity. |
| ConfIdeS | Protocol 20-HMedIdeS-17/ ConfIdeS: An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care. The study is for End-Stage Renal Disease (ESRD) patients that are highly sensitized and are active on the OPTN waiting list for a kidney transplant. | Click here to read more about this opportunity. |
| InnAVasc Arteriovenous Graft Technology | If you have kidney failure and are currently undergoing hemodialysis or are expected to require hemodialysis, you may be a candidate for a clinical study evaluating the InnAVasc Arteriovenous Graft – an investigational graft that may make the graft easier to locate under your skin, safer to stick for dialysis, more durable, less likely to bleed after your dialysis session when compared to standard care grafts, and allows for immediate use to reduce catheter time. | Click here to read more about this opportunity. |
